Lymphatic filariasis among the Yakurr people of Cross River State, Nigeria
© Iboh et al.; licensee BioMed Central Ltd. 2012
Received: 1 February 2012
Accepted: 11 September 2012
Published: 19 September 2012
In order to initiate a disease elimination programme for lymphatic filariasis based on mass drug administration, a proper understanding of the geographical distribution and degree of risk is essential.
An investigation of lymphatic filariasis due to Wuchereria bancrofti was carried out among 785 people in four communities of Yakurr Local Government Area of Cross River State, Nigeria between March and August, 2009. Finger prick blood smear samples collected from the subjects were examined for W. bancrofti using standard parasitological protocol. The subjects were also screened for clinical manifestations of lymphatic filariasis.
Of the 785 persons examined, 48 (6.1%) were positive for microfilariae in their thick blood smear. There was a significant difference in the prevalence of lymphatic filariasis among the various age groups (P < 0.01) although peak prevalence occurred between 41 – 60 years. There was no significant difference in prevalence and density with respect to sex (P > 0.05). The overall mean microfilarial density of the infected individuals was 5.6mf/50 μl. There was a significant variation (P < 0.01) in mean microfilarial density within the communities, ranging from 4.7 to 6.4 mf/50 μl. The only clinical sign found in the study area was lymphoedema of the leg recording 2 (0.3%) prevalence.
The National Lymphatic Filariasis Elimination Programme should intervene by expanding the distribution of albendazole and ivermectin to all endemic areas including Yakurr Local Government Area of Cross River State, Nigeria.
Lymphatic filariasis is a major public health problem, affecting 120 million people living in 72 countries of the world, 39 African countries carry over a third of the global burden of lymphatic filariasis. Lymphatic filariasis is associated with dermatitis, elephantiasis and hydrocoele. Severe complications could include lymphoedema and elephantiasis of the limbs or genitalia, which adversely affect personal and social life, and limit occupational activities.
Filariasis is one of the most common causes of permanent disability worldwide creating the highest disease burden in terms of DALYs among tropical disease. The disease is a major cause of poverty as it leads to economic burden for those affected, their dependants, their communities and their country as a whole[4, 5]. Consequently, in 1998, the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) was formed to support the lymphatic elimination programme in endemic countries and The World Health Organization launched a Global Programme to Eliminate Lymphatic Filariasis (GPELF), which has the goal of eliminating the disease as a public health problem by 2020. The strategy aimed at achieving this goal is twofold. First, interrupt transmission of the LF parasite by delivering single annual doses of diethylcarbamazine (DEC) or ivermectin plus albendazole to the entire eligible population living in areas where the disease is endemic (defined as areas where the prevalence of microfilaraemia or antigenaemia is ≥1%). In addition to interrupting transmission, mass drug administration (MDA) provides significant collateral health benefits, such as reduced morbidity from intestinal worms and ectoparasites (for example, lice). Second, alleviate suffering and disability by introducing basic measures, such as improved hygiene and skin care, for those with lymphoedema and by providing surgery for men with hydrocele.
Available literature on the disease from both the North and Central parts of Nigeria and the report of a postal survey by the Nigerian Lymphatic Filariasis Elimination Programme (NLFEP) have shown that lymphatic filariasis is endemic[8–10]. One of the greatest challenges confronting the NLFEP is the lack of information on the distribution and degree of risk of the disease in the country.
The NLFEP of the Federal Ministry of Health, with the assistance of The Carter Centre has set 2015 as the year to eliminate the disease in Nigeria. Even though a number of investigators[11–14] have carried out studies in different parts of the country, there is need to collate epidemiological data because most areas of the country have not yet received attention
The main objective of this study was to investigate the status of this infection amongst the Yakurr people of Cross River State, Nigeria, prior to the launch of the lymphatic filariasis elimination programme in Cross River Basin, where annual mass administration of ivermectin has been going on for several years through Community Directed Treatment.
A preliminary survey of lymphatic filariasis caused by W. bancrofti was carried out among the Yakurr people of Cross River State, Nigeria. This area is situated between latitude 5°40′ and 6°N and longitude 7°55′ and 8°33′ E. The communities randomly selected for the investigation included; Idomi, Ijom, Lekpankom and Ntankpo. They are The African Programme for Onchocerciasis Control (APOC) Community Directed Treatment with Ivermectin (CDTi) communities, and have been receiving treatment since 1995. They have a therapeutic coverage of over 80%. The Yakurr people are mainly farmers cultivating mainly yams, cassava and rice. This area is located in the tropical rainforest belt with high annual rainfall, high relative humidity and high mean annual temperature.
Permission to conduct this survey was obtained from The Centre for Clinical Governance Research and Training of the Ministry of Health, Cross River State, Nigeria, before the commencement of the study. Consent was also obtained from the Paramount Ruler and the respective Community Heads of the Yakurr Local Government Area where investigation was carried out. They were informed of the nature, scope and purpose of the study. Peripheral night blood collection from the subjects and inconveniences of pains on pricking the finger were explained. Participation of individuals in these communities was voluntary.
The sample for the present survey was drawn from household selected through systematic sampling with random start, selecting every alternate household. Each selected household was considered as a sampling unit as previously described. Participants from the various communities were mobilized by the respective Community Heads to gather in their respective Community Health centre between 2300 and 0300 hours. Information about age, sex, history of previous treatment with ivermectin were obtained from each individual and recorded on a standard form. A total of 785 finger prick blood samples were collected from the four communities between March and August, 2009.
Giemsa stained thick blood smear was used for the identification of microfilariae using a binocular microscope. Microfilariae of W. bancrofti were identified based on specific morphological features and sizes as described by Cheesbrough. They were counted in each for the infected morphological density and recorded on the standard individual forms. The keys of Cheesbrough were used to identify and distinguish microfilariae of W. bancrofti from microfilariae of other filarial worms, Mansonella perstans and Loa loa
Trained medical personnel recruited for this study examined all the 785 persons for clinical manifestation of lymphatic filariasis. All males and females were examined for signs of the limb and breast elephantiasis. Males had their genitals examined for hydrocoele and scrotal elephantiasis. Clinical manifestations were staged as described.
The differences in the distribution of lymphatic filariasis among communities and age groups were determined using the analysis of variance (ANOVA). The prevalence of infection between sexes, and age was determined by chi-square test, while student ‘t’ test determined differences in density. All data were analyzed using SPSS for windows version 10.0 (SPSS Inc Chicago, IL).
Prevalence (%) and clinical manifestation of lymphatic filariasis due to W. bancrofti by community
Population sampled (%)
Prevalence (%) of W. bancrofti infection by age
Age range (Years)
No. of individuals examined
No (%) positive for microfilariae of LF
1 – 20
21 – 40
41 – 60
61 – 80
Prevalence (%) and mean density of W. bancrofti infection by community and sex
Total number of individuals examined
Number (%) infected
Mean microfilarial density mf/50 μl
Total mf/ 50 μl
The microfilarial density indicated a mean overall value of 5.6 mf/50 μl of blood, (Table3). There was no significant difference in the density of microfilaraemia between males and females (P > 0.05) Table3. There was a significant variation (P < 0.01) in microfilarial density between the communities it ranged from 4.7mf/50 μl in Lekpankom to 6.4mf/50 μl in Ijom.
The only clinical manifestation of lymphatic filariasis due to W. bancrofti in the study population was lymphoedema (Table1). Out of the 785 persons examined, 2 (0.3%) showed stage 2 lymphoedema of both legs. No other clinical manifestation were encountered.
This preliminary survey of lymphatic filariasis among 785 Yakurr people of Cross River State, Nigeria revealed an overall prevalence of 48 (6.1%). This is consistent with the results obtained by Udoidung et al. and Targema et al.[14, 18] who reported 6.5% and 5.5% in Benue State and in some rural communities of the Lower Cross River Basin, Nigeria respectively. Higher prevalence was found in other studies of lymphatic filariasis due to W. bancrofti in Nigeria. Work by Okon et al. reported 15.5% among Mbembe people of Cross River State, Anosike et al. reported 16.9% among the Ezza people of Ebonyi State while Mbah and Njoku observed 18.8% in Aguata Local Government Area of Anambra State. The lower prevalence in the present study could be due the current Government effort of CDTi project where ivermectin is being distributed in some communities in the Cross River State, including those of the Yakurr people. Ivermectin has the ability to eliminate microfilariae of other filarial parasites such as M. perstans and Loa loa including W. bancrofti. The potential benefit of overlapping interventions have recently been highlighted elsewhere, and is an important consideration for determining the risk of lymphatic filariasis in Nigeria.
This study indicated a gradual increase in prevalence with increasing age range, thereafter there was a decline at the age range of 61 – 80 years. The prevalence observed among the 61 – 80 year age group may be due to resistance to new infection resulting from acquired immunity. However, a peak prevalence of 12.1% was recorded in the 41 – 60 year age group during this study. In a related study, Anosike observed a gradual increase in prevalence with increasing age and a peak prevalence at age range of 40 – 49 years. In this study, the high prevalence observed between 21 – 60 years might be due to the fact that these age groups are involved in intense occupational activities such as farming and fishing. Typical Yakurr farmers spend three-quarters of the daytime in outdoor farming activities, hence they were exposed to more mosquito vectors in water pools prevailing in their cassava farms and rice fields.
The prevalence rate for males and females were 18 (5.7%) and 30 (6.4%) respectively. There was no statistically significant difference between both sexes. Both men and women engage equally in the activities that exposed them to the vectors. They were also exposed to the same living conditions. Most houses in the area had mud walls, thatched roofs, no ceiling; hence permitting movement of insects in and out as was earlier reported. Also exposure to various breeding sites of the vectors due to their poor environmental and unhygienic conditions might have accounted for the equal prevalence of both males and females.
A mean microfilarial density of 5.6mf/50 μl of night peripheral blood was found among the infected population of Yakurr people of Cross River State, Nigeria. Okon et al. found a mean density of 9.9mf/50 μl among the Mbembe people of Obubra Local Government Area of Cross River State. While Anosike found a mean microfilarial density of 10.4mf per 20 mm3 of night peripheral blood. Microfilarial density is an important index in the epidemiology, treatment and control of human filariasis in endemic foci. The mean microfilarial density of 5.6 mf/50 μl obtained in this study is lower than the 9.9mf/50 μl and 9mf/50 μl obtained by[12, 14] respectively. In spite of the low microfilarial density in the study area, there is a need for implementation of the various control measures in this locality. The low parasite density might also be due to the ongoing CDTi in the area, since the drug has an effect on W. bancrofti[21, 23].
The only clinical manifestation of the lymphatic filariasis infection was lymphoedema found in 2 (0.3%) of the entire study population. This has been reported by several investigators as the cause of disability and disfigurement in endemic areas[24–26]. Hydrocele which is an important clinical manifestation of lymphatic filariasis was not observed in this study as was the case with previous investigations in the state[12, 14]. The low prevalence of lymphoedema and absence of hydrocele might be due to human or parasite genetic differences or transmission related factors.
This is the first documented report of lymphatic filariasis among the Yakurr people of Cross River State, Nigeria. This will thus enrich the epidemiological baseline data of the disease in Nigeria. The Government should intervene by expanding the distribution of albendazole in addition to the CDTi that is presently going on in the communities. Preventative chemotherapy and transmission control (PCT) with albendazole and ivermectin annually in populations at risk where lymphatic filariasis prevalence of more than or equal to 1% is the basis of lymphatic filariasis elimination programmes[28, 29].
The authors are indeed grateful to Dr. Patrick E. Ubi, the Medical Superintendent of Ugep General Hospital, Yakurr Local Government Area of Cross River State who assisted in the blood collection and also screened the human subjects for the clinical manifestations of the infection. We also acknowledge the untiring assistance of the following nurses Otoh Esekpa, Eteng J. Eteng and Ibiang I. Iboh during the field work.
- WHO: Global programme to eliminate lymphatic filariasis: Progress report on mass drug administration 2010. Wkly Epidemiol Rec. 2011, 86: 377-388.Google Scholar
- WHO: Lymphatic filariasis infection and disease control strategies. 1994, Geneva: World Health Organisation, TDR/CTD/FIL/PENANG/94.1Google Scholar
- Ottesen EA, Hoopes PJ, Bradley M, Biswas E: The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis. 2008, 2 (10): 317-10.1371/journal.pntd.0000317.View ArticleGoogle Scholar
- Huppatz C, Capuano C, Palmerk Kelly PM, Durrheim DN: Lessons from the pacific programme to eliminate lymphatic filariasis: a case study of 5 countries. BMC Infect Dis. 2009, 9: 92-10.1186/1471-2334-9-92.PubMed CentralView ArticlePubMedGoogle Scholar
- Ruberanziza F, Mupfasoni D, Karibushi B, Rujeni N, Kabanda E, Kabera M, Kaberuka T, Nizeyimana V, Kramer MH, Mukabayire O: Mapping of lymphatic filariasis in Rwanda. Journal of lymphoedema. 2009, 4 (1): 20-23.Google Scholar
- Bockarie MJ, Molyneux DH: The end of lymphatic filariasis?. BMJ. 2009, 338: b1686-10.1136/bmj.b1686.View ArticlePubMedGoogle Scholar
- WHO: Progress report 2000–2009 and strategic plan 2010–2020 of the Global Programme to Eliminate Lymphatic Filariasis: halfway towards eliminating lymphatic filariasis. 2010, WHO/HTM/NTD/PCT/ 2010.6 GenevaGoogle Scholar
- Wijeyaratne PM, Verma OP, Singha P, Osuhor PC, Motha B, Saha AL, Slotboom AB, Deleon A, Bandipo AB: Epidemiology of filariasis in Malumfashi District of Northern Nigeria. Indian J Med Res. 1982, 76: 534-544.PubMedGoogle Scholar
- Ufomadu GO, Nwoke BE, Akoh JI, Sato Y, Ekejindu GO, Uchida A, Shiwaku K, Tambau M, Ugomo KK: The occurrence of loaisis, mansonellosis and wuchereriasis in the Jarawa River Valley, Central Nigeria. Acta Trop. 1990, 48 (2): 137-147. 10.1016/0001-706X(90)90053-3.View ArticlePubMedGoogle Scholar
- Anosike JC, Azoro VA, Nwoke BEB, Keke RI, Okere AN, Oku EE, Ogbulie JN, Tony-Njoku RF, Okoro OU, Nwosu DC: Dracunculiasis in the north-eastern border of Ebonyi State, South-Eastern Nigeria. An Int J Hyg Environ Health. 2003, 206 (1): 45-51. 10.1078/1438-4639-00176.View ArticleGoogle Scholar
- Anosike JCN: The status of human filariasis in north-western zone of Bauchi State, Nigeria. Appl Parasitol. 1994, 35: 133-140.PubMedGoogle Scholar
- Okon OE, Iboh CI, Opara KN: Bancroftian filariasis among the Mbembe people of Cross River State, Nigeria. J Vect Borne Dis. 2010, 47 (2): 91-96.Google Scholar
- Omudu EA, Okafor FC: Rapid epidemiological and socio-cultural appraisal of lymphatic filariasis amongst the Igede ethnic group in Benue State, Nigeria. Nigerian J Parasitol. 2007, 28 (2): 118-124.Google Scholar
- Udoidung NI, Braide IE, Opara KN, Atting IA, Adie H: Current status of Bancroftian filariasis in rural communities of the Lower Cross River Basin, Nigeria. Parasitological and Clinical aspects. J Public Health. 2008, 16: 383-388. 10.1007/s10389-008-0189-6.View ArticleGoogle Scholar
- FMAMA: Weather Record, Calabar, Cross River State. 2009, Nigeria: Federal Ministry of Aviation and Meterological AgencyGoogle Scholar
- Cheesbrough M: District laboratory practice in Tropical Countries, part 1. 2005, Cambridge: Cambridge University Press, 454-2View ArticleGoogle Scholar
- McMahon JZ, Magayuka SA, Kolstrup N, Mosha FW, Bushrod FM, Abarn DE, Bryan JH: Studies on the transmission and prevalence of bancroftian filariasis in four coastal villages in Tanzania. Ann Trop Med Parasitol. 1981, 75: 415-431.PubMedGoogle Scholar
- Targema CN, Onwuliri CO, Mafuya HB, Mwansal GS, Aida A, Eigege A, Ityonzughal C, Kal A, Orkurga B, Jinadu MY: Mapping of lymphatic filariasis in Benue State, Nigeria. Nigerian J Parasitol. 2008, 29 (1): 55-60.Google Scholar
- Anosike JC, Nwoke BE, Ajayi EG, Onwuliri CO, Okoro OU, Oku EE, Asor JE, Amajuoyi OU, Ikpeama CA, Ogbusu FI, Meribe CO: Lymphatic filariasis among Ezza people of Ebonyi State Eastern Nigerian. Ann Agric Environ Med. 2005, 12: 181-186.PubMedGoogle Scholar
- Mbah DC, Njoku OO: Prevalence of lymphatic filariasis (LF) in Ovari, Aguata Local Government Area of Anambra State, Nigeria. Nigerian J Parasitol. 2002, 21: 95-102.Google Scholar
- WHO: WHO Technical report series. Onchocerciasis and its control. 1995, 852-Google Scholar
- Kelly Hope A, Thomas BC, Bockarie MJ, Molyneux DH: Lymphatic filariasis in the Democratic Republic of Congo; Micro – stratification overlap mapping (MOM) as a prerequisite for control and surveillance. Parasit Vectors. 2011, 4: 178-10.1186/1756-3305-4-178.PubMed CentralView ArticlePubMedGoogle Scholar
- Koroma JB, Bangura MM, Hodges MH, Balr MS, Zhang Y, Bockarie MJ: Lymphatic filariasis mapping by Immunochromatographic test cards and baseline microfilaria survey prior to mass drug administration in Sierra Leone. Parasit Vectors. 2012, 5: 10-10.1186/1756-3305-5-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Yadav JS: A special issue on lymphatic filariasis. ENVIS New Letter. 2004, 2 (Issue 1): May 2004Google Scholar
- Schwartz BE, Miller J, l-Galley R: Hydrocoele. 2010, Medsape Education: Filarial Webmed ProfessionalsGoogle Scholar
- Leder K, Weller PF, Baron EL: Epidemiology, pathogenesis and clinical features of lymphatic filariasis. 2010, 94 Sawyer Road, Waltham, MA 02453: UPTO DATE INCGoogle Scholar
- Shiferaw W, Kebede T, Graves PM, Golasa M, Gebre T, Mosher AW, Tadesse A, Sime H, Lambiyo T, Panickes KN, Richards FO, Hailen A: Lymphatic filariasis in Western Ethiopia with special emphasis on prevalence ofWuchereria bancroftiantigenaemis in and around Onchocerciasis endemic areas. Trans R Soc Trop Med Hyp. 2012, 106: 117-127. 10.1016/j.trstmh.2011.10.006.View ArticleGoogle Scholar
- WHO: Preventive chemotherapy in human helminthiasis. 2006, Geneva: World Health OrganizationGoogle Scholar
- Hodges MH, Smith SJ, Fussum D, Koroma JB, Conteh A, Sonnie M, Sesay S, Zhang Y: High coverage of mass drug administration for lymphatic filariasis in rural and non-rural settings in the Westerns Area Sierra Leone. Parasit Vectors. 2010, 3: 120-10.1186/1756-3305-3-120.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.